0001628280-23-029393.txt : 20230814 0001628280-23-029393.hdr.sgml : 20230814 20230814162314 ACCESSION NUMBER: 0001628280-23-029393 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230814 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avalo Therapeutics, Inc. CENTRAL INDEX KEY: 0001534120 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450705648 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37590 FILM NUMBER: 231170688 BUSINESS ADDRESS: STREET 1: 540 GAITHER ROAD STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 410-522-8707 MAIL ADDRESS: STREET 1: 540 GAITHER ROAD STREET 2: SUITE 400 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: Cerecor Inc. DATE OF NAME CHANGE: 20111102 8-K 1 avtx-20230814.htm 8-K avtx-20230814
0001534120false00015341202023-08-142023-08-14


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  

FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2023

AVALO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)  
Delaware
(State or other jurisdiction of incorporation)
001-3759045-0705648
(Commission File Number)(IRS Employer Identification No.)
540 Gaither Road, Suite 400, Rockville, Maryland 20850
(Address of principal executive offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code: (410) 522-8707

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par ValueAVTXNasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 1.01. Entry into a Material Definitive Agreement.

As previously disclosed in Current Report on Form 8-K filed on June 8, 2021, Avalo Therapeutics, Inc. (the “Company”), entered into a Venture Loan and Security Agreement (as amended, from time to time, the “Note”), issued on June 4, 2021, to certain institutional investors (the “Holders”). As of July 20, 2023, the Holders asserted that a default and event of default has occurred due to a material adverse change in the Company’s business (the “Existing Default”).

Also as previously disclosed in Current Report on Form 8-K filed on July 21, 2023, on July 20, 2023, the Company entered into a forbearance agreement (the “Forbearance Agreement”) with the Holders, pursuant to which the Holders agreed to forbear from enforcing its full remedies related to the Existing Default until the earliest of (i) August 15, 2023, (ii) the occurrence of any default or event of default (other than the Existing Default) under the Note, or (iii) the occurrence of a breach by the Company of any provision in the Forbearance Agreement. In exchange for the Holders agreeing to enter the Forbearance Agreement, the Company agreed to maintain cash on deposit in deposit accounts subject to an Account Control Agreement (as defined in the Note) in favor of the Collateral Agent (as defined in the Forbearance Agreement) in an amount (the “Cash Deposit”) not less than the sum of (a) $3,000,000 plus (b) one-hundred percent (100%) of the aggregate cash proceeds received by Company as a result of the any future sale of the Company’s equity securities while the Forbearance Agreement is in effect.

On August 14, 2023, the Company and the Holders entered into a Second Forbearance Agreement (the “Second Forbearance Agreement”) whereby the forbearance period was extended to September 15, 2023. In addition, the amount of the Cash Deposit was set at $3,000,000 without any addition of cash of proceeds from future sales of the Company’s equity securities during the forbearance period.

Except as set forth above, all other terms, conditions and rights of the Note remain in full force and effect.

The foregoing description of the Second Forbearance Agreement does not purport to be complete and is subject to, and qualified by, the full text of such document, a copy of which is filed as Exhibit 10.1 and is incorporated by reference herein.

Item 8.01. Other Information.

On August 14, 2023, the Company received a notice from Apollo AP43 Limited alleging that the Company is in breach of the License Agreement between them dated July 29, 2022 by virtue of owing $837,522 to a service provider under the terms of that license. The notice formally initiates a dispute resolution process under the license, beginning with further negotiations between the companies’ executive officers. The Company intends to attempt to negotiate a settlement, but it might not be successful in doing so.

Based upon preliminary estimates and information available to the Company, the Company had approximately $5.4 million in cash and cash equivalents as of August 11, 2023. This estimate of the Company’s cash and cash equivalents as of August 11, 2023 is preliminary, unaudited and is subject to change upon completion of the Company’s financial statement closing procedures and the audit of the Company’s consolidated financial statements.


1


Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits:

2


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVALO THERAPEUTICS, INC.
Date: August 14, 2023By:/s/ Christopher Sullivan
Christopher Sullivan
Chief Financial Officer



3
EX-10.1 2 ex-101secondforbearanceagr.htm EX-10.1 Document
    Exhibit 10.1

SECOND FORBEARANCE AGREEMENT

This SECOND FORBEARANCE AGREEMENT (this “Agreement”) is made as of August 14, 2023, by and among (i) Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.), a Delaware corporation (the “Borrower”), (ii) Horizon Credit II LLC, Horizon Funding Trust 2019-1, Horizon Funding I, LLC, and Powerscourt Investments XXV Trust, as lenders (collectively, the “Lenders”), and (iii) Horizon Technology Finance Corporation, as collateral agent for the Lenders (in such capacity, the “Collateral Agent” and collectively with the Lenders, the “Secured Parties”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Loan Agreement (as defined below).
WHEREAS, on June 4, 2021, the Borrower, the Lenders, and the Collateral Agent entered into a Venture Loan and Security Agreement (as the same may be amended, restated, supplemented or modified from time to time, the “Loan Agreement”);
WHEREAS, pursuant to the Loan Agreement, the Lenders provided Loans to the Borrower in the aggregate original principal amount of $35,000,000, as evidenced by a (i) Secured Promissory Note (Loan A) in the original principal amount of $5,000,000, executed by the Borrower and other parties thereto in favor of Horizon Credit II LLC, dated as of June 4, 2021, (ii) Secured Promissory Note (Loan B) in the original principal amount of $5,000,000, executed by the Borrower in favor of Horizon Funding Trust 2019-1, dated as of June 4, 2021, (iii) Secured Promissory Note (Loan C) in the original principal amount of $2,500,000, executed by the Borrower in favor of Horizon Funding I, LLC, dated as of June 4, 2021, (iv) Secured Promissory Note (Loan D) in the original principal amount of $7,500,000, executed by the Borrower in favor of Powerscourt Investments XXV Trust, dated as of June 4, 2021, (v) Secured Promissory Note (Loan E) in the original principal amount of $5,000,000, executed by the Borrower in favor of Horizon Funding I LLC, dated as of July 30, 2021, (vi) Secured Promissory Note (Loan F) in the original principal amount of $5,000,000, executed by the Borrower in favor of Horizon Credit II LLC, dated as of July 30, 2021, (vii) Secured Promissory Note (Loan G) in the original principal amount of $2,500,000, executed by the Borrower in favor of Horizon Credit II LLC, dated as of September 29, 2021, and (viii) Secured Promissory Note (Loan H) in the original principal amount of $2,500,000, executed by the Borrower in favor of Horizon Credit II LLC, dated as of September 29, 2021;

WHEREAS, the Lenders have asserted that as of the date hereof a Default and Event of Default has occurred under Section 8.4 of the Loan Agreement, due to the occurrence of events prior to the date of this Agreement that constitute a material adverse change in the Borrower’s business (the “MAC Default”);

WHEREAS, the Secured Parties would be entitled to exercise their rights and remedies under the Loan Agreement as a result of the MAC Default;

WHEREAS, on July 20, 2023, the Secured Parties entered into a Forbearance Agreement (the “Forbearance Agreement”), whereby the Secured Parties agreed, among other things, to forbear from exercising their rights and remedies in respect of the MAC Default until, at the latest, August 15, 2023 (the “Forbearance Termination Date”);

WHEREAS, the Borrower has requested that the Secured Parties, among other things, extend the Forbearance Termination Date to September 15, 2023 (the “Extended Forbearance Termination Date”); and




WHEREAS, subject to the terms and conditions of this agreement, and the covenants of the Borrower set forth herein, the Secured Parties have agreed as provided herein.

NOW, THEREFORE, in consideration of the promises herein contained and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1.    Event of Default. The Borrower agrees that the MAC Default constitutes an Event of Default under the Loan Agreement. The Borrower represents and warrants that, except for the MAC Default, no Default or Event of Default has occurred under the Loan Agreement that has not been waived by the Secured Parties. The Borrower acknowledges and agrees that, as a result of the occurrence of the MAC Default, each Secured Party has the immediate and unrestricted right to accelerate the maturity of the Obligations and to exercise any and all rights and remedies available to it under the Loan Documents and/or at law or in equity.

2.    Agreement to Forbear. Each Secured Party hereby agrees to forbear from exercising remedies in respect of the MAC Default through and until the earliest to occur of (a) the Extended Forbearance Termination Date, (b) the occurrence of any Default or Event of Default other than the MAC Default or (c) a breach of any provision of this Agreement (such period the “Extended Forbearance Period”). At the end of the Extended Forbearance Period, all agreements hereunder to forbear shall terminate automatically and without further notice or action, and be of no force and effect, and the effect of such termination shall be to permit each Secured Party to immediately exercise any and all rights and remedies available to it under the Loan Agreement or any other Loan Document.

3.    Extension of Extended Forbearance Period. In the sole discretion of the Secured Parties and without obligation, at the request of the Borrower, after the Extended Forbearance Termination Date the Secured Parties may renew or extend the Extended Forbearance Period, or grant additional forbearance periods.

4.    Representations and Warranties of Borrower. The Borrower hereby represents and warrants to the Secured Parties as of the date of this Agreement:

a.    The Borrower is a corporation duly organized and validly existing under the laws of its state of incorporation and qualified and licensed to do business in, and is in good standing in, any state or country in which the conduct of its business or its ownership of properties requires that it be so qualified, except where the failure to do so could not reasonably be expected to have a material adverse effect on the Borrower’s business.
b.    The Borrower has all necessary corporate power and authority to execute, deliver, and perform in accordance with the terms thereof, this Agreement. The Borrower has all requisite corporate power and authority to own and operate its properties and to carry on its business as now conducted.
c.    The execution and delivery of this Agreement, and the consummation of the transactions contemplated herein have each been duly authorized and delivered by all necessary action on the part of the Borrower and constitute legal, valid and binding obligations of the Borrower, enforceable in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application relating to or affecting the enforcement of creditors’ rights or by general principles of equity.
d.    The Borrower represents and warrants that, except for the MAC Default, no Default or Event of Default has occurred and is continuing under the Loan Documents.
2



5.    Borrower’s Covenant. The Borrower covenants and agrees, for the benefit of the Collateral Agent and the Lenders, that commencing as of the date of this Agreement, the Borrower shall maintain, at all times, cash on deposit in deposit accounts subject to an Account Control Agreement in favor of the Collateral Agent in an amount not less than Three Million Dollars ($3,000,000).
6.    Acknowledgments and Agreements.
a.    The Borrower acknowledges, agrees, and represents and warrants that, immediately prior to the effective date of this Agreement, pursuant to the Loan Documents, the Borrower is legally and validly indebted to the Lenders in respect of the Loans in the outstanding principal amount of Thirteen Million Seven Hundred Forty-Three Thousand Three Hundred Seventy-Three and 17/100 Dollars ($13,743,373.17), plus interest, fees, and other amounts accrued and accruing thereon or related thereto, including, without limitation, Lenders’ Expenses related to the MAC Default and this Agreement, the Loan A Final Payment, the Loan B Final Payment, the Loan C Final Payment, the Loan D Final Payment, the Loan E Final Payment, the Loan F Final Payment, the Loan G Final Payment, and the Loan H Final Payment.

b.    The Borrower acknowledges, affirms and agrees that the Secured Parties hold valid, perfected, enforceable, first priority security interests (except for Permitted Liens) in the Collateral as security for all Obligations under the Loan Documents (including, for the avoidance of doubt, all Obligations arising from or related to this Agreement).
c.    The Borrower acknowledges and agrees that it has no defense, claim, offset, abatement, or deduction to any Obligations and no cause of action, claim, defense, or counter-claim against any Secured Party in any way relating to the Loan Documents, any transactions contemplated thereby, or any Secured Party’s actions thereunder.
d.    The Borrower acknowledges and agrees that (i) any failure of the Borrower to perform any of the covenants set forth in Section 5 of this Agreement shall constitute an immediate “Event of Default” under the Loan Agreement and (ii) upon the occurrence of any such Event of Default, the Secured Parties shall have the immediate and unrestricted right to exercise any and all rights and remedies available under the Loan Documents and/or at law and in equity.
e.    The Borrower acknowledges, agrees, and affirms that (i) this Agreement shall constitute a “Loan Document” for all purposes, including, without limitation, the definitions of “Obligations” and “Lenders’ Expenses;” (ii) the definition of “Obligations” shall include all amounts, obligations, covenants, and duties owing by the Borrower to the Secured Parties, of any kind and description, under this Agreement; and (iii) the definition of “Lenders’ Expenses” shall include the costs and expenses set forth in Section 8 hereof.
f.    The Borrower hereby ratifies and confirms all terms and provisions of this Agreement, the Loan Agreement, and the other Loan Documents and all other documents, instruments, or agreements executed in connection therewith and except as expressly set forth herein, agrees that all of such terms and provisions remain in full force and effect and have not been modified or amended in any respect.
7.    Release. In consideration of each Secured Party’s willingness to enter into this Agreement, the Borrower does hereby release, remise and forever discharge each Secured Party and its current and former officers, directors, managers, partners, members, employees, agents, attorneys, affiliates, advisors, consultants, shareholders and representatives (collectively, the
3



Released Parties”) of and from (and covenants not to sue the Released Parties for) any and all debts, demands, actions, causes of action, suits, accounts, covenants, contracts, agreements, claims, rights, damages, losses or liabilities of any nature whatsoever, whether at law or in equity, anticipated or unanticipated, fixed or contingent, known or unknown, which arose at any time prior to the date hereof, or which hereafter could arise based on any act, fact, transaction, cause, matter, or thing which occurred prior to the date hereof related to the Borrower, the Loans, the Loan Documents, or any documents or instruments delivered pursuant thereto or the transactions governed thereby or the dealings of the Borrower with the Released Parties with respect thereto. The Borrower hereby expressly waives any and all rights it may have against the Released Parties under Section 1542 of the California Civil Code (“Section 1542”) or any similar law, and the Borrower acknowledges that it may not invoke in any manner any claims released in this Agreement. The Borrower is aware that Section 1542 provides as follows: “[a] general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor or released party.”
8.    Fees and Expenses. The Borrower agrees to pay (a) concurrently with the execution of this Agreement a forbearance fee to the Secured Parties in an amount equal to Five Thousand Dollars ($5,000) and (b) on demand, all reasonable, documented costs and expenses of the Secured Parties (including, without limitation, reasonable, documented attorneys’ fees and expenses) incurred in connection with (i) the preparation, negotiation, execution, delivery, and administration of this Agreement, and (ii) the MAC Default.

9.    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Connecticut, other than legal principles related to conflicts of laws.

10.    No Waiver. No course of dealing heretofore or hereafter between the Borrower and any Secured Party, and no failure or delay on the part of any Secured Party in exercising any rights or remedies under the Loan Documents or existing at law or in equity, shall operate as a waiver of any rights or remedies of any Secured Party with respect to the Obligations, and no single or partial exercise of any rights or remedies hereunder shall operate as a waiver or preclusion to the exercise of any other rights or remedies that any Secured Party may have in regard to the Obligations.

11.    Modification. This Agreement may not be modified in any manner, except by written agreement signed by the Borrower and the Secured Parties.

12.    Execution in Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

13.    Severability. Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity without invalidating the remainder of such provision or the remaining provisions of this Agreement.

14.    Good Faith Negotiations. The Borrower acknowledges that this Agreement is the result of good faith negotiations, that it has carefully considered all of its alternatives and that it has entered into this Agreement without duress or coercion of any kind.

4



15.    Entire Agreement. This Agreement constitutes the entire understanding and agreement among the parties hereto and supersedes any prior or contemporaneous written or oral understanding with respect to the subject matter hereof.

    [the remainder of this page intentionally left blank]
5



IN WITNESS WHEREOF, this Second Forbearance Agreement has been duly executed by each of the undersigned as of the day and year first set forth above.


BORROWER
AVALO THERAPEUTICS, INC.
By:/s/ Garry Neil
Name:Garry Neil
Title:Chief Executive Officer



[Signature Page to Second Forbearance Agreement - Avalo]



COLLATERAL AGENT:
HORIZON TECHNOLOGY FINANCE CORPORATION
By:/s/ Daniel S. Devorsetz
Name:Daniel S. Devorsetz
Title:Executive Vice President, Chief Operating Officer and Chief Investment Officer
 
LENDERS:


HORIZON CREDIT II LLC, as a Lender


By:/s/ Daniel S. Devorsetz

Name:Daniel S. Devorsetz

Title:Executive Vice President, Chief Operating

 
HORIZON FUNDING TRUST 2019-1, as a Lender
  
By:Horizon Technology Finance Corporation, its
agent
 By:/s/ Daniel S. Devorsetz
 Name:Daniel S. Devorsetz
 Title:Executive Vice President, Chief Operating
  
 
HORIZON FUNDING I, LLC, as a Lender
 
 By:/s/ Daniel S. Devorsetz
 Name:Daniel S. Devorsetz
 Title:Manager
[Signature Page to Second Forbearance Agreement - Avalo]







POWERSCOURT INVESTMENTS XXV, TRUST, as a Lender
By: 1485 Management, LLC, as Trust's Agent
/s/ Glenn Guszkowski
Name:Glenn Guszkowski
Title:Authorized Signatory



[Signature Page to Second Forbearance Agreement - Avalo]

EX-101.SCH 3 avtx-20230814.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avtx-20230814_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 avtx-20230814_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page Document
Aug. 14, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 14, 2023
Entity Registrant Name AVALO THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37590
Entity Tax Identification Number 45-0705648
Entity Address, Address Line One 540 Gaither Road, Suite 400
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 410
Local Phone Number 522-8707
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol AVTX
Entity Emerging Growth Company false
Entity Central Index Key 0001534120
Amendment Flag false
XML 7 avtx-20230814_htm.xml IDEA: XBRL DOCUMENT 0001534120 2023-08-14 2023-08-14 0001534120 false 8-K 2023-08-14 AVALO THERAPEUTICS, INC. DE 001-37590 45-0705648 540 Gaither Road, Suite 400 Rockville MD 20850 410 522-8707 false false false false Common Stock, $0.001 Par Value AVTX false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 21 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Document Sheet http://www.avalotherapeutics.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports avtx-20230814.htm avtx-20230814.xsd avtx-20230814_lab.xml avtx-20230814_pre.xml ex-101secondforbearanceagr.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "avtx-20230814.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 21 }, "contextCount": 1, "dts": { "inline": { "local": [ "avtx-20230814.htm" ] }, "labelLink": { "local": [ "avtx-20230814_lab.xml" ] }, "presentationLink": { "local": [ "avtx-20230814_pre.xml" ] }, "schema": { "local": [ "avtx-20230814.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avtx", "nsuri": "http://www.avalotherapeutics.com/20230814", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "avtx-20230814.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page Document", "menuCat": "Cover", "order": "1", "role": "http://www.avalotherapeutics.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "avtx-20230814.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.avalotherapeutics.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001628280-23-029393-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-029393-xbrl.zip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